Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

ion of this is that spontaneous bleeding events, which are a potential unwanted side effect if Factor VIII is completely inhibited, should not occur. Hence, there would be no need for the monitoring of coagulation parameters in the patient.

ThromboGenics is developing TB-402 in collaboration with BioInvent International.

In comparison to other current anticoagulants that require daily dosage, TB-402 has a prolonged half-life that will allow for a single-dose treatment in orthopaedic surgery patients and/or once-a-month administration for long-term stroke prevention in atrial fibrillation (AF).

Staphylokinase

- Initiation of Phase III by Bharat Biotech International Ltd in India.

ThromboGenics has entered into a partnership with Bharat Biotech to continue the clinical development and commercialization of THR-100. This novel variant of Recombinant Staphylokinase is initially being developed by Bharat in India for the treatment of acute myocardial infarction (AMI), or heart attack. Given the commercial strengths of Bharat in this market and the clinical advantages of THR-100, it is hoped that this novel product will quickly become the market leader for the treatment of heart attacks in India. It is currently anticipated that THR-100 Phase III will be started in India in the third quarter.

Patrik De Haes, COO of ThromboGenics, commenting on today's release said, "ThromboGenics is confident that 2008 will be a transformational year for the Company. The important clinical milestones that we expect to achieve will further highlight the attractiveness of our clinical pipeline of innovative vascular biopharmaceuticals. These milestones will also provide us with a platform for signing partnership deals, which are an important element of our strategy to develop ThromboGenics into an important player in the areas of vascular disease, eye disease and cancer."

ThromboGenics will provide a further update when the Company reports its
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Diagnostics Inc. (TSX:V: SQD), a life sciences company that ... advanced microarray diagnostics, today announced it has appointed ... team. In his capacity as CFO he will ... development stage to a commercially successful company including ... market strategy and to secure funding to drive ...
(Date:3/3/2015)... NEW YORK , March 3, 2015 ... that Jeffrey I.D. Lewis has joined the ... Practice, resident in the New York ... also handles trademark matters, as well as other intellectual ... registered patent attorney, Mr. Lewis represents both plaintiffs and ...
(Date:3/3/2015)...  Rosa & Co. LLC, a drug development advisory ... today announced it has two posters scheduled to be ... and Therapeutics meeting in New Orleans, LA ... - http://photos.prnewswire.com/prnh/20150302/179058LOGO   Bristol- Myers ... a quantitative systems pharmacology approach for immuno-oncology drug development ...
(Date:3/3/2015)... 03, 2015 Cambridge Semantics, the leading ... technology, today announced that it has been named to ... in Knowledge Management.’ , To create the list ... analysts and system integrators who identify organizations dedicated to ... right information to the right people at the right ...
Breaking Biology Technology:SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2
... ... Akt/mTOR inhibitor -, JAMAICA ... has presented three presentations at the 2008,annual meeting of the ... P529 is a non-steroidal, synthetic, small molecule dual acting,anti-angiogenic ...
... DEERFIELD, Ill., April 15 , What and ... CHICAGO (Carotid,intima-media tHICkness in Atherosclerosis using pioGlitazOne) published,today ... thickness (CIMT) with ACTOS(R) (pioglitazone HCl) was,associated with ... when compared to glimepiride., The increased effect ...
... /PRNewswire/ - The acceptance of Peros, oral,delivery platform ... achievement by Benchmark Biolabs, a full service,biopharmaceutical product ... oversees the operation and,management of the Peros production ... biotechnology campus in Lincoln, NE., By obtaining ...
Cached Biology Technology:Paloma Pharmaceuticals to Present at the American Association for Cancer Research 2Paloma Pharmaceuticals to Present at the American Association for Cancer Research 3Paloma Pharmaceuticals to Present at the American Association for Cancer Research 4New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 2New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 3Another industry first enabled by Benchmark Biolabs - Peros' oral delivery platform and vaccine facility licensed by the USDA 2
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... console others who are in distress, using physical touches and ... access journal PeerJ . The findings are the first ... Plotnik, who began the research as a graduate student of ... that elephants seem to be highly intelligent and empathic animals, ...
... is linked to more rapid infant growth and to genetic ... JAMA Pediatrics today (Monday). , The studies investigated how ... namely lower satiety responsiveness (a reduced urge to eat in ... increased urge to eat in response to the sight or ...
... dogmas is that complex life on Earth could only evolve when ... But now studies of a small sea sponge fished out of ... levels of oxygen in order to live and grow. The ... could the first small primitive cells evolve into the diversity of ...
Cached Biology News:Asian elephants reassure others in distress 2Asian elephants reassure others in distress 3Why tackling appetite could hold the key to preventing childhood obesity 2Theory on origin of animals challenged: Animals needs only extremely little oxygen 2
...
...
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
Request Info...
Biology Products: